| I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $85.1M | ||||||||
| Company | Location | Date | Amt. (M) | Investors | ||||
| Cytovia Inc. | Irvine, Calif. | 4/1 | $10 | Cytovia was spun off from CoCensys Inc. | ||||
| (1st round) | in 1/98; in this 1st financing round, it | |||||||
| raised $10M from Domain Associates, | ||||||||
| Crosspoint Venture Partners, Sanderling | ||||||||
| Ventures and Forrest, Binkley & Brown | ||||||||
| Kosan Biosciences | Burlingame, Calif. | 4/8 | $15 | Kosan sold $15M in convertible preferred | ||||
| Inc. (2nd round) | stock to new investors, led by S.R. One Ltd. | |||||||
| and including the Goldman Sachs Group, | ||||||||
| Lombard Odier and AG-Biotech Capital; | ||||||||
| they were joined by current investors | ||||||||
| Alta Partners, Sofinnova, Walden and | ||||||||
| Kosan cofounder Daniel Santi | ||||||||
| Modex Therapeutics | Lausanne, Switzerland | 4/27 | $8 | This financing round was oversubscribed; | ||||
| SA (2nd round) | a group of European investors, led by Atlas | |||||||
| Venture, Banexi Ventures, 3i plc and Novar- | ||||||||
| tis Venture Fund, was joined by current | ||||||||
| investors Alta Partners, Alta Berkeley and | ||||||||
| Lombard Odier Immunology Fund | ||||||||
| Molecular | Palo Alto, Calif. | 4/28 | $9.5 | Investors in this financing round included | ||||
| Applications Group | Bay City Capital, Coral Ventures, Delphi | |||||||
| Inc. | Ventures, Medicus Venture Partners, | |||||||
| Morgenthaler Ventures and private investor | ||||||||
| Timothy Springer | ||||||||
| Orchid Biocomputer | Princeton, N.J. | 4/13 | $27.5 | Orchid raised $27.5M through a Series C | ||||
| Inc. (3rd round) | convertible preferred stock financing, which | |||||||
| was led by Orbimed Advisors LLC and the | ||||||||
| Invesco Funds Group. Other investors | ||||||||
| included Oxford BioScience Partners, WPG | ||||||||
| Farber, Millennium Ventures of Motorola | ||||||||
| Inc. and SmithKline Beecham plc | ||||||||
| Oxagen Ltd. | Abingdon, U.K. | 4/6 | $13.7 | Oxagen raised £8.2M ($13.7M) from new | ||||
| (1st round) | investors 3i plc and Advent Ltd. and pre- | |||||||
| vious investors The Wellcome Trust, the | ||||||||
| University of Oxford and 2 unnamed pri- | ||||||||
| vate investors | ||||||||
| Reprogen Inc. | Irvine, Calif. | 4/17 | $1.4 | The company raised $1.4M in the 2nd | ||||
| (1st round) | tranche of its financing, bringing the total | |||||||
| to $6.5M (the 1st tranche closed 2/13/98); | ||||||||
| new investors included Life Science Ven- | ||||||||
| tures and Hambrecht & Quist LLC | ||||||||
| II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM CORPORATE PARTNERS: $12.0M | ||||||||
| Company | Partner | Amt. | Triggering | Details (Date) | ||||
| (Symbol) | (Symbol; Country) | (M) | Event | |||||
| Atrix Laboratories | Block Drug Corp. | $7 | Approvable | The companies entered an agreement in | ||||
| Inc. (ATRX) | (NASDAQ:BLOCA) | letter on | 12/96 for Block Drug to market Atridox | |||||
| Atridox | in North America; the FDA sent Atrix an | |||||||
| approvable letter for Atridox for treating | ||||||||
| periodontal disease, triggering the $7M | ||||||||
| milestone payment (4/8) | ||||||||
| Isis | Ciba Vision Corp. | $5 | Submission | The companies entered an agreement in | ||||
| Pharmaceuticals Inc. | (division of Novartis | of NDA on | 7/97 for Ciba Vision to market fomivirsen | |||||
| (ISIP) | AG; Switzerland) | fomivirsen | worldwide; the partners jointly submitted | |||||
| an NDA for the antisense drug (for treating | ||||||||
| AIDS-related cytomegalovirus retinitis), | ||||||||
| triggering the $5M milestone payment (4/8) | ||||||||
| III. PIPE/REG. S FINANCINGS: $0M | ||||||||
| There were no PIPE/Reg. S financings in April. | ||||||||
